Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for \textit{M. tuberculosis} isolates that were resistant to second-line anti-TB drugs during 2000–2004. We defined extensively drug-resistant TB (XDR TB) as MDR TB with further resistance to >3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR TB isolates, 347 (9.9%) met criteria for XDR TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR TB are crucial for protection of public health and control of TB.

Multidrug-resistant tuberculosis (MDR TB) has been documented in nearly 90 countries and regions worldwide (1); 424,203 cases of MDR TB were estimated to have occurred in 2004, which is 4.3% of all new and previously treated TB cases (2). Treatment for MDR TB patients requires use of second-line drugs for ≥24 months. These drugs are more costly, toxic, and less effective than first-line drugs used for routine treatment of TB (3–6). As with other diseases, resistance to TB drugs results primarily from nonadherence by patients, incorrect drug prescribing by providers, poor quality drugs, or erratic supply of drugs (7).

To facilitate treatment of MDR TB in resource-limited countries, where most TB cases occur (1,2), the World Health Organization (WHO) and its partners developed the Green Light Committee, which helps ensure proper use of second-line drugs, to prevent further drug resistance (8). Nonetheless, the Green Light Committee encountered numerous anecdotal reports of MDR TB cases with resistance to most second-line drugs. Once a strain has developed resistance to second-line drugs, these new TB strains are even more difficult to treat with existing drugs. Untreated or inadequately treated patients are at increased risk of spreading their disease in the community, which could lead to outbreaks in vulnerable populations and widespread emergence of a lethal, costly epidemic of drug-resistant TB, reminiscent of the MDR TB outbreaks in the early 1990s (9–13). Therefore, to determine whether these anecdotal reports were isolated events, early evidence of an emerging epidemic, or the occurrence of virtually

\[\text{Worldwide Emergence of Extensively Drug-resistant Tuberculosis}\]

N. Sarita Shah,∗1 Abigail Wright,† Gill-Han Bai,‡ Lucia Barrera,§ Fadila Boulahbal,¶ Nuria Martín-Casabona,مب Francis Drobniewski,** Chris Gilpin,†† Marta Havelková,‡‡ Rosario Lepe,§§ Richard Lump,¶¶ Beverly Metchock,* Francoise Portaels,## Maria Filomena Rodrigues,### Sabine Rüscher-Gerdes,#### Armand Van Deun,##### Veronique Vincent,###### Kayla Laserson,* Charles Wells,* and J. Peter Cegielski*

*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †World Health Organization, Geneva, Switzerland; ‡Korean Institute of Tuberculosis, Seoul, Republic of Korea; §National Institute of Infectious Diseases, Buenos Aires, Argentina; ¶Institut Pasteur d’Algérie, Alger, Algeria; #Hospital Universitari Vall d’Hebron, Barcelona, Spain; **Health Protection Agency, London, United Kingdom; ††Prince Charles Hospital, Brisbane, Queensland, Australia; ‡‡National Institute of Public Health, Scrobarova, Czech Republic; §§Institute of Public Health of Chile, Providencia Santiago, Santiago, Chile; ¶¶Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia; ###Institute of Tropical Medicine, Antwerp, Belgium; ####National Institute of Health, Porto, Portugal; †††National Reference Center for Mycobacteria, Borstel, Germany; and ‡‡‡Institut Pasteur, Paris, France

1Current affiliation: Albert Einstein College of Medicine, Bronx, New York, USA
2Member: World Health Organization/International Union against Tuberculosis and Lung Diseases Network of Supranational Reference Laboratories
3Current affiliation: World Health Organization, Geneva, Switzerland
untreatable forms of drug-resistant TB that had not been described previously in different parts of the world, we characterized and quantified the frequency of second-line–drug resistance in several geographic regions.

We sought to determine the extent to which highly resistant *Mycobacterium tuberculosis* strains have been identified by the international laboratories that participate in the Network of Supranational Reference Laboratories (SRLs). The SRL Network consists of 25 highly proficient TB laboratories on 6 continents. These laboratories collaborate with national reference laboratories to strengthen culture and drug-susceptibility testing capacity and to provide quality control for the WHO/International Union Against Tuberculosis and Lung Diseases Global Project on Anti-TB Drug Resistance (14).

**Methods**

**Participants**

From November 2004 through November 2005, we surveyed the global SRL Network. All SRL directors were invited to participate during the 2004 annual SRL directors meeting, by individual mailings, and by personal phone calls. Drug-susceptibility testing results were requested for *M. tuberculosis* isolates that had been tested for resistance to first-line drugs and second-line drugs during 2000–2004. Two SRLs were not eligible because they did not test for second-line drugs or tested for <3 classes of second-line drugs.

The 14 SRLs that provided data for this study support 112 TB laboratories in 80 countries worldwide (Figure 1). SRLs serve as international reference laboratories to a wide geographic area, performing drug-susceptibility testing that may not be available in a country (e.g., for second-line drugs) and providing quality assurance for first-line–drug testing. Most SRLs also serve as the national reference laboratory for the country in which they are located; they receive varying proportions of isolates from their own and other countries for surveillance, clinical diagnosis, and quality assurance. First-line–drug susceptibility testing is performed on all isolates; second-line–drug susceptibility testing is usually limited to isolates from patients known or suspected to have drug-resistant TB. Of the 14 participating SRLs, not all tested for all 6 classes of second-line drugs, and 4 did not submit data for the entire survey period.

In contrast, the SRL in the Republic of Korea serves as the national reference laboratory and routinely performs an extended diagnostic panel of drug-susceptibility testing on isolates from culture-positive TB patients referred from health centers, hospitals, and clinics in the Republic of Korea. This SRL tests all isolates for 6 classes of second-line drugs; thus, data from the Republic of Korea reflect most culture-positive cases and provide a close approximation to a population estimate of prevalence. Because of the large number of isolates received and because sampling for these isolates is systematically different from that at the other SRLs (testing of all TB patients in the Republic of Korea vs testing of patients more likely to have drug-resistant TB in other SRLs), resistance patterns for the Republic of Korea were analyzed separately from those for the other SRLs.

**Laboratory Methods**

Among participating SRLs, different but internationally accepted methods were used to test for second-line drug resistance (details available upon request). Validation of drug-susceptibility testing results for second-line drugs was not performed as part of this survey, but as part of their role as global reference laboratories, all SRLs participate in international proficiency testing for first-line drugs. Quality assurance procedures for second-line–drug susceptibility testing have not been developed; as a proxy for quality assurance, we examined the accuracy of second-line–drug susceptibility testing among isolates susceptible to the 4 main first-line drugs (isoniazid [INH], rifampin [RIF], ethambutol, and streptomycin). On the basis of known mechanisms of drug resistance, finding an isolate that is susceptible to all first-line drugs and resistant to second-line drugs is unlikely (7).

**Procedures and Definitions**

A standardized reporting form requested anonymous data for all isolates tested for resistance to ≥3 second-line drug classes during 2000–2004. Data were abstracted from the records, electronic or paper, depending on laboratory practices for data management. Results were submitted for 1 isolate per patient. Because SRLs rarely receive multiple isolates from the same patient, reporting of the same patient more than once was unlikely (B. Metchock and Extensively Drug-resistant Tuberculosis Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 3, March 2007 381

Figure 1. Shading indicates 48 countries that submitted at least 1 isolate to participating Supranational Reference Laboratories, 2000–2004. See Table 4 for complete list of participating countries.
G.H. Bai, pers. comm.). No specimens were collected for this study; we used only data from records of isolates that had already been tested. Limited clinical information about the patient was available with each isolate. Consistent data were available for country of origin and date of drug-susceptibility testing. Data about age and TB treatment history were available for <10% of patients, so analysis was not considered reliable for these variables.

To best compare data for the study samples with data from the Global Drug Resistance Survey and other population-based drug-resistance surveillance, we analyzed first-line–drug resistance patterns according to standard methods used in anti-TB–drug resistance surveys (1). These patterns included any drug resistance, monoresistance (resistance to only the 1 specified drug), polyresistance (resistance to ≥2 first-line drugs, but which drugs not specified), and multidrug resistance (resistance to at least INH and RIF, with or without other drugs).

We defined 6 classes of second-line drugs as follows: aminoglycosides other than streptomycin (e.g., kanamycin and amikacin), cyclic polypeptides (e.g., capreomycin), fluoroquinolones (e.g., ofloxacin, ciprofloxacin, levofloxacin, and moxifloxacin), thioamides (e.g., prothionamide and ethionamide), serine analogs (e.g., cycloserine and terizidone), and salicylic acid derivatives (e.g., paraaminosalicylic acid).

For this survey we created a consensus definition that incorporates second-line–drug susceptibility results and is based on international guidelines for management of drug-resistant TB (15). The mainstay of an MDR TB treatment regimen consists of 1 injectible drug (e.g., aminoglycoside or cyclic polypeptide) and a fluoroquinolone; additional drugs from the remaining classes are added until the total reaches 4–6 drugs to which the organism is susceptible. If the infecting organism is resistant to ≥3 second-line drug classes, designing a treatment regimen with sufficient drugs that are known to be effective against TB is difficult. Thus, we defined extensively drug-resistant TB (XDR TB) isolates as those meeting the criteria established for MDR TB plus resistance to ≥3 of the 6 classes of second-line drugs.

Second-line–drug resistance patterns were analyzed by geographic region from which the isolate was submitted to the SRL. Regions were grouped into epidemiologically meaningful categories on the basis of prevalence of TB and MDR TB (1,16). This retrospective survey was evaluated and approved as public health surveillance by the US Centers for Disease Control and Prevention (CDC).

Results

We received data for 18,462 patients from 14 (61%) of 23 eligible SRLs. We excluded those patients tested before 2000 (n = 223), tested after 2004 (n = 14), or tested for resistance to <3 classes of second-line drugs (n = 535). Our final study sample consisted of 17,690 patients whose isolates were tested for resistance to ≥3 second-line drugs during 2000–2004 (Figure 2). Of these, 11,939 (67.5%) patients were from the Republic of Korea and 5,751 (32.5%) were from the remaining SRLs.

First-line–Drug Susceptibility

Among isolates from patients from the 13 SRLs other than the Republic of Korea, 3,765 (65.5%) were resistant to ≥1 first-line TB drug (Table 1). Of these, 3,305 (58.5%) were resistant to at least INH and 2,345 (41.5%) were resistant to at least RIF. Among isolates from the Republic of Korea patients, 2,508 (21%) had resistance to any drug; most (n = 2,196; 18.4%) were resistant to INH.

Single-drug resistance was found for isolates from 884 (15.4%) patients from the 13 SRLs; 456 (8.1%) of these were resistant to INH and 99 (1.8%) to RIF. Among isolates from patients from the Republic of Korea, 952 (8%) displayed single-drug resistance, 666 (5.6%) to INH and 148 (1.2%) to RIF.

Polyresistance other than MDR TB was seen for isolates from 651 (11.5%) patients from the 13 SRLs and 258 (2.2%) from the Republic of Korea SRL. Not all SRLs routinely tested for resistance to pyrazinamide.

Multidrug resistance (i.e., MDR TB) was present in isolates from 2,222 (39.4%) patients from the 13 SRLs and 1,298 (10.9%) from the Republic of Korea. Resistance to

Figure 2. Selection of study sample and summary of drug-resistance patterns of isolates. SRL, Supranational Reference Laboratory. *Tested before 2000 or after 2004 (n = 247) or tested for resistance to <3 classes of second-line drugs (n = 535). †Data for ethambutol resistance missing for 5 isolates.
all first-line drugs tested (i.e., MDR TB with additional resistance to ethambutol and streptomycin) was found in isolates from 1,017 (18.6%) patients from the 13 SRLs and 233 (2%) from the Republic of Korea SRL.

Second-line–Drug Susceptibility

Among patients from the 13 SRLs, resistance to aminoglycosides was detected in 489 (8.7%) isolates and to fluoroquinolones in 298 (5.3%) (Table 2). Among isolates from Republic of Korea patients, resistance was most commonly seen to fluoroquinolones (n = 524, 4.4%) and thioamides (n = 259, 2.2%).

From all SRLs, isolates that were resistant to at least INH and RIF (i.e., MDR TB; n = 3,520) and tested for susceptibility to \( \geq 3 \) second-line drugs were combined for analysis of second-line–drug resistance patterns. Resistance to \( \geq 1 \) class of second-line drug was present in 1,542 (43.8%) MDR TB patients (Table 3). The most commonly observed patterns were resistance to aminoglycosides (n = 630, 18.3%), fluoroquinolones (n = 673, 19.3%), and thioamides (n = 605, 19.3%).

MDR TB patients whose isolates had further resistance to \( \geq 3 \) classes of second-line drugs were classified as XDR TB (Table 3). A total of 347 (9.9%) MDR TB patients met criteria for XDR TB. According to the revised Global XDR TB Task Force definition (www.who.int/mediacentre/news/notes/2006/np29/en/index.html), 234 (6.6%) isolates met criteria for XDR TB. Among XDR TB patients, combination drug-resistance patterns included 90 (3.4%) with resistance to aminoglycosides, capreomycin...
and fluoroquinolones; 102 (3.4%) with resistance to aminoglycosides, fluoroquinolones, and thioamides; and 94 (3.8%) with resistance to fluoroquinolones, thioamides, and para-aminosalicylic acid. Nearly half (n = 167, 48.1%) of all XDR TB isolates were resistant to all 4 first-line drugs, bringing the total to >7 drugs to which the isolate was resistant.

The proportion of XDR TB patients by region is shown in Table 4. Among the group of industrialized nations, 53 (6.5%) MDR TB patients met criteria for XDR TB. Among patients from Russia and Eastern Europe, 55 (13.6%) MDR TB patients met criteria for XDR TB. Among patients from the Republic of Korea, 200 (15.4%) MDR TB patients, who accounted for 1.7% of all Mycobacterium tuberculosis isolates tested, met criteria for XDR TB. A drug-resistance survey of 447 culture-positive new patients and patients undergoing retreatment in Abkhazia, Republic of Georgia, found that of 63 MDR TB patients, 2 (3%) had additional resistance to 3 second-line drug classes, consistent with XDR TB (18). More recently, clusters of XDR TB have been reported in South Africa and Iran (19,20) and have been associated with HIV infection and rapid and high death rates.

The emergence of new strains of TB that are resistant to second-line drugs, especially in settings where TB control programs have become unable to adequately monitor treatment regimens for MDR TB, is cause for concern. After the resurgence of TB in industrialized countries during the 1980s and increased awareness of this global problem, implementation of strong TB control programs based on the principles of the global directly observed treatment strategy, short course (DOTS) improved treatment outcomes and reduced TB and MDR TB incidence in several countries. This framework for DOTS, promulgated by WHO, and the pilot MDR TB management projects (DOTS-Plus projects) became the basis for programmatic management of MDR TB, which has demonstrated feasibility and effectiveness in low- and middle-income countries (5,15). However, second-line drugs are available worldwide outside of well-organized TB-control programs (WHO, unpub. data).

Improper treatment of drug-resistant TB, such as using too few drugs, relying on poor quality second-line drugs, and failing to ensure adherence to treatment, will likely lead to increases in XDR TB. Strengthening basic TB programs and infection control measures is crucial for preventing the selective pressure and environments in which resistant strains are transmitted from person to person.

### Table 3. Second-line–drug resistance patterns for multidrug-resistant Mycobacterium tuberculosis isolates, 2000–2004†‡

<table>
<thead>
<tr>
<th>Pattern</th>
<th>No. tested</th>
<th>No. (%) resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any resistance (total)</td>
<td>3,520</td>
<td>1,542 (43.8)</td>
</tr>
<tr>
<td>Aminoglycosides (AG)§</td>
<td>3,442</td>
<td>630 (18.3)</td>
</tr>
<tr>
<td>Capreomycin (CM)</td>
<td>2,743</td>
<td>279 (10.2)</td>
</tr>
<tr>
<td>Fluoroquinolones (FQ)</td>
<td>3,492</td>
<td>673 (19.3)</td>
</tr>
<tr>
<td>Thioamides (TA)</td>
<td>3,132</td>
<td>605 (19.3)</td>
</tr>
<tr>
<td>Cycloserine (CS)</td>
<td>2,615</td>
<td>141 (5.4)</td>
</tr>
<tr>
<td>Para-aminosalicylic acid (PAS)</td>
<td>2,860</td>
<td>450 (15.7)</td>
</tr>
<tr>
<td>Extensively drug-resistant TB (XDR TB, total)¶</td>
<td>3,520</td>
<td>347 (9.9)</td>
</tr>
<tr>
<td>AG + CM + FQ</td>
<td>2,656</td>
<td>90 (3.4)</td>
</tr>
<tr>
<td>AG + CM + TA</td>
<td>2,498</td>
<td>77 (3.1)</td>
</tr>
<tr>
<td>CM + FQ + TA</td>
<td>280</td>
<td>50 (19.2)</td>
</tr>
<tr>
<td>AG + FQ + TA</td>
<td>3,040</td>
<td>102 (3.4)</td>
</tr>
<tr>
<td>AG + FQ + CS</td>
<td>139</td>
<td>39 (28.1)</td>
</tr>
<tr>
<td>FQ + TA + PAS</td>
<td>2,505</td>
<td>94 (3.6)</td>
</tr>
</tbody>
</table>

*Tested for ≥3 second-line drug classes; SRLs, Supranational Reference Laboratories.
†Not all isolates were tested for each second-line drug class (with the exception of the Republic of Korea SRL), so results are reported as a proportion of isolates tested to the specified class of drugs. For combination resistance patterns, results are reported as a proportion of isolates tested to all of the classes of drugs in the specific combination.
‡Cells are not mutually exclusive.
§Other than streptomycin (e.g., kanamycin, amikacin).
¶XDR TB, extensively drug-resistant tuberculosis, i.e., multidrug-resistant tuberculosis (resistant to at least isoniazid and rifampin) with additional resistance to ≥3 classes of second-line drugs.
son. Additionally, MDR TB programs that rely on quality-assured and internationally recommended treatment regimens according to WHO guidelines must be scaled up and strengthened to stem further second-line–drug resistance and spread of XDR TB. The Green Light Committee provides a global mechanism to help affected countries achieve these steps. A commentary published in 2000 predicted that “failure to institute [the] entire DOTS-Plus package is likely to destroy the last tools available to combat [TB], and may ultimately result in the victory of the tubercle bacillus over mankind” (21). XDR TB is an indirect indicator of program failure to adequately diagnose, prevent, and treat MDR TB.

Table 4. Extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis isolates, by region, 2000–2004*  

<table>
<thead>
<tr>
<th>Geographic region</th>
<th>Total no. isolates tested, n†</th>
<th>Total MDR TB patients, n (% of all isolates tested)</th>
<th>Total XDR TB patients, n (% of MDRTB patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industrialized nations‡</td>
<td>2,499</td>
<td>821 (32.9)</td>
<td>53 (6.5)</td>
</tr>
<tr>
<td>Latin America§</td>
<td>985</td>
<td>543 (55.1)</td>
<td>32 (5.9)</td>
</tr>
<tr>
<td>Eastern Europe¶ and Russia</td>
<td>1,153</td>
<td>406 (35.2)</td>
<td>55 (13.6)</td>
</tr>
<tr>
<td>Africa and Middle East#</td>
<td>665</td>
<td>156 (23.5)</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Asia (other than Republic of Korea)**</td>
<td>391</td>
<td>274 (70.1)</td>
<td>4 (1.5)</td>
</tr>
<tr>
<td>Republic of Korea</td>
<td>11,939</td>
<td>1,298 (10.9)</td>
<td>200 (15.4)</td>
</tr>
<tr>
<td>Total†</td>
<td>3,418</td>
<td></td>
<td>345</td>
</tr>
</tbody>
</table>

*Region from which isolate was submitted to Supranational Reference Laboratory. MDR TB, multidrug-resistant tuberculosis; XDR TB, extensively drug-resistant tuberculosis, i.e., multidrug-resistant tuberculosis (resistant to at least isoniazid and rifampicin) with additional resistance to ≥3 classes of second-line drugs.

†Total no. of isolates tested for resistance to ≥3 second-line drug classes, including aminoglycosides (amikacin or kanamycin), polypeptides (capreomycin), fluoroquinolones (ofloxacin or ciprofloxacin), thioamides (ethionamide or prothionamide), cycloserine, and para-aminosalicylic acid.

‡United States, Canada, United Kingdom, countries in Western Europe (Ireland, Portugal, Germany, France, Belgium, Spain), Japan, and Australia.

§Argentina, Bolivia, Brazil, Chile, Ecuador, Guyana, French Guiana, Peru, Mexico, Guatemala, El Salvador, Costa Rica.

¶Republic of Georgia, Czech Republic, Azerbaijan, Armenia.

Afghanistan, Algeria, Egypt, Tunisia, Botswana, Burundi, Cameroon, Central African Republic, Côte d’Ivoire, Djibouti, Madagascar, Rwanda, South Africa, Senegal, Uganda.

**Bangladesh, Indonesia, Papua New Guinea, Thailand, East Timor.

††For ≥2 XDR TB patients, data were missing about geographic region.

Documenting the emergence of XDR TB requires a laboratory-based diagnosis that relies on first- and second-line–drug susceptibility testing. A limitation to accurate detection of XDR TB is that existing tests for resistance to second-line drugs are not yet standardized and are less reproducible than tests for resistance to INH and RIF. Lack of international recommendations for use, as well as lack of standardization and the historical unavailability of MDR TB treatment in the public sector, has limited use of second-line–drug susceptibility testing on a wider scale. As access to treatment with second-line drugs increases, standardized methods, improved diagnostics, and quality assurance for second-line–drug susceptibility testing are urgently needed to enable reliable testing and design of appropriate treatment regimens. Although internationally accepted methods were used by all laboratories, the precise methods and drug concentrations used varied among participating SRLs (22). Because these SRLs represent some of the most highly performing laboratories on 6 continents, results of drug-susceptibility testing are credible within the context of stated limitations. Initial studies that standardized different methods for second-line–drug susceptibility testing have been completed (23–26), but more are needed.

Our study has other limitations. The numbers reported for XDR TB probably represent an underestimate of the true number of cases because not all SRLs and not all national reference laboratories test for all 6 classes of second-line drugs. In the absence of test results for all 6 classes of second-line drugs, we speculate, on the basis of a patient’s TB treatment history and known patterns of drug cross-resistance, that many other unidentified patients are likely to have had and died from XDR TB. For example, an MDR TB isolate that is also resistant to an aminoglycoside and a fluoroquinolone but that has not been tested for the other second-line drug classes is very likely to be resistant to an additional second-line drug for the following reasons: INH and ethionamide have a 15%–20% rate of cross-resistance (27); kanamycin and capreomycin cross-resistance is common, ranging from 20%–60% (CDC, unpub. data) (28,29); and in this study, isolates that were resistant to all 4 first-line drugs as well as an aminoglycoside and a fluoroquinolone were 70%–80% likely to be resistant to at least 1 additional class of second-line drug.

Another limitation is that data from most SRLs were drawn from a convenience sample of isolates and reflect referral bias. Thus, these data can not be considered representative of a patient population or region, and actual denominators are difficult to determine. For this reason, although estimates of prevalence are possible, they cannot be generalized to the local or regional population. However, our study is the first to report XDR TB patients in multiple geographic regions; future systematic surveys are needed to determine the true extent of this disease. Data from the Republic of Korea reflect a more comprehensive policy for drug-susceptibility testing and provide an estimate of the population prevalence in this setting.
However, the 10.9% rate of MDR TB for the Republic of Korea is higher than rates reported from other national drug resistance surveys and may reflect other unknown referral biases (1).

Lastly, we had limited clinical information about each patient because information submitted to each SRL varied and was not reliably available for inclusion in the analysis. Data about TB treatment history, patient age and sex, or HIV status are not routinely collected by all laboratories. Genotyping data were not available to confirm whether XDR TB isolates are related to W variant of the Beijing strain, a highly drug-resistant strain of *M. tuberculosis* responsible for large nosocomial outbreaks in New York in the early 1990s (30).

Despite these limitations, our survey provides the first documentation of the emergence of XDR TB as a serious worldwide public health threat. XDR TB was identified on 6 continents and is significantly associated with worse treatment outcomes than MDR TB (31,32). The emergence of XDR TB, coupled with the increased use of second-line drugs, suggests that urgent measures are needed to improve rational use of quality-assured second-line drugs. In addition, population-based surveillance for second-line–drug susceptibility testing is needed to better describe the magnitude of XDR TB worldwide, track trends, and plan a public health response. Indeed, the convergence of XDR TB with the HIV epidemic may undermine gains in HIV prevention and treatment programs and requires urgent interventions. These interventions include ensuring adherence to recommended international standards of care aimed at promptly and reliably diagnosing TB, ensuring adherence to recommended treatment regimens with demonstrated efficacy, implementing infection control precautions where patients congregate, and improving laboratories’ capacity to accurately and rapidly detect drug-resistant *M. tuberculosis* isolates so that patients can receive effective treatment (33). Other unmet needs include further development of international standards for second-line–drug susceptibility testing, new anti-TB drug regimens, and better diagnostic tests for TB and MDR TB. Such measures are crucial if future generations are to be protected from potentially untreatable TB.

**Acknowledgments**

We thank Kenneth G. Castro, Michael F. Iademarco, Mario Raviglione, Paul Nunn, and Ernesto Jaramillo for technical assistance and critical appraisal of the manuscript.

Dr Shah is an internist and epidemiologist with Albert Einstein College of Medicine. She is also a guest researcher with the Division of Tuberculosis Elimination at CDC, where she was an Epidemic Intelligence Service Officer at the time of this study. Her research interests focus on TB and HIV coinfection, drug resistance, and global health.

**References**


Address for correspondence: N. Sarita Shah, Department of Medicine, Division of General Internal Medicine, Albert Einstein College of Medicine, 111 E. 210 St, Bronx, NY 10467, USA; email: sshah@montefiore.org